Cabozantinib s-malate by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
22 Dec 2023 06:00 GMT
… -malate overview
Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s … cervical cancer, metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell …
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
10 Sep 2022 07:37 GMT
… carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC) and breast cancer. The … in phase 1 (trial identifier: XL184-011): XL092 demonstrated a 71% …
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
10 Sep 2022 07:39 GMT
… carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC) and breast cancer. The … in phase 1 (trial identifier: XL184-011): XL092 demonstrated a 71% …